There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers.
INTRODUCTION ACE-031 is a soluble form of activin receptor type IIB ( ActRIIB ) . ACE-031 promotes muscle growth by binding to myostatin and other negative regulators of muscle mass . METHODS This double-blind , placebo-controlled study evaluated the safety , pharmacokinetics , and pharmacodynamics of ACE-031 in 48 healthy , postmenopausal women r and omized to receive 1 dose of ACE-031 ( 0.02 - 3 mg/kg s.c . ) or placebo ( 3:1 ) . RESULTS ACE-031 was generally well-tolerated . Adverse events included injection site erythema . Mean ACE-031 AUC(0-∞ ) and C(max ) increased linearly with dose ; mean T(½ ) was 10 - 15 days . Statistically significant increases in mean total body lean mass ( 3.3 % ; P = 0.03 , by DXA ) and thigh muscle volume ( 5.1 % ; P = 0.03 , by MRI ) were observed at day 29 in the 3 mg/kg group . Statistically significant changes in serum biomarkers suggest ACE-031 also improved bone and fat metabolism . CONCLUSIONS Single-dose ACE-031 treatment was generally well-tolerated and result ed in increases in muscle mass in healthy postmenopausal women
There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .